Obesity pharmacotherapy: what is next?

Mol Aspects Med. 2013 Feb;34(1):71-83. doi: 10.1016/j.mam.2012.10.005. Epub 2012 Oct 24.

Abstract

The increase in obesity in the Unites States and around the world in the last decade is overwhelming. The number of overweight adults in the world surpassed 1 billion in 2008. Health hazards associated with obesity are serious and include heart disease, sleep apnea, diabetes, and cancer. Although lifestyle modifications are the most straightforward way to control weight, a large portion of the population may not be able to rely on this modality alone. Thus, the development of anti-obesity therapeutics represents a major unmet medical need. Historically, anti-obesity pharmacotherapies have been unsafe and minimally efficacious. A better understanding of the biology of appetite and metabolism provides an opportunity to develop drugs that may offer safer and more effective alternatives for weight management. This review discusses drugs that are currently on the market and in development as anti-obesity therapeutics based on their target and mechanism of action. It should serve as a roadmap to establish expectations for the near future for anti-obesity drug development.

Publication types

  • Review

MeSH terms

  • Anti-Obesity Agents / pharmacology*
  • Appetite / drug effects
  • Drug Delivery Systems
  • Humans
  • Life Style
  • Lipase / antagonists & inhibitors
  • Lipase / metabolism
  • Neuropeptides / metabolism
  • Obesity / drug therapy*
  • Pancreatic Hormones / metabolism
  • Synaptic Transmission / drug effects
  • Weight Loss / drug effects

Substances

  • Anti-Obesity Agents
  • Neuropeptides
  • Pancreatic Hormones
  • Lipase